PD-1/PDL1pathway in breast cancer. SCHüTZ F,STEFANOVIC S,MAYER L,et al. Oncol Res Treat . 2017Schutz F, Stefanovic S, Mayer L, von Au A, Domschke C, Sohn C. PD-1/ PD-L1 pathway in breast cancer. Oncol Res Treat. 2017;40:294-7....
2.O'neill RE, Cao X. Co-Stimulatory and co-inhibitory pathways in cancer immunotherapy. Adv Cancer Res (2019) 143:145–94. 3.Schütz F, Stefanovic S, Mayer L, Von Au A, Domschke C, Sohn C. PD-1/ PD-L1 pathway in breast cancer...
PD-1/PD-L1 免疫药物在肿瘤的治疗中确实发挥了重要的作用,其机制主要阻断 PD-1 和 PD-L1 之间的相互作用,可以显著增强免疫功能,抑制肿瘤生长。 根据新型抗肿瘤药物临床应用指导原则,肺癌 PD-1/PD-L1 治疗药物有 7 种,患者在使用时需要临床医生充分评估患者病情后,并根据患者的经济条件合理选择最合适的免疫药物...
Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 ...
PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. J Transl Med. 2015;13:5. DOI: 10.1016/j.cellimm.2012.07.001 Hong S, Chen N, Fang W, et al. Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: ...
At present, only tumour tissue programmed death-ligand 1 (PD-L1) and mismatch repair deficiency status are approved as theranostic biomarkers for programmed cell death-1 (PD-1)/PD-L1 inhibitors in BC. However, due to the complexity of tumour microenvironment (TME) and cancer response to ...
Programmed death ligand-1 (PD-L1)/PD-1 checkpoint extensively serves as a central mediator of immunosuppression. A tumor-promoting role for abundant PD-L1 in several cancers is revealed. However, the importance of PD-L1 and how the PD-L1 expression is controlled in breast cancer remains obscur...
Initially, immune checkpoint monotherapies were not very successful, making breast cancer less immunogenic. Although, recent reports support the presence of tumor infiltrating lymphocytes (TILs) in breast cancer that make it favorable for PD-1/PD-L1 mediated immunotherapy, which is effective in PD-...
笔者个人较为看好共同阻断HPK1和PD-L1发挥出的增强抗肿瘤效应,期待国产HPK1抑制剂可以和国产PD-1/PD-L1小分子抑制剂联手,创出佳绩。 PD-1/PD-L1小分子抑制剂临床试验考量: 2、满足需求 定点突破 在兼顾安全性和有效性的前提下,小分子抑制剂...
escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway[J]．Cell Death Differ, 2020, 27(6): 1765-1781.DOI: 10.1038/s41418-019-0460-0.ZhangP, SuDM, LiangM, et al.Chemopreventive agents induce programmed death-1-ligand 1(PD-L1) surface expression in breast cancer ...